With 1.87 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.16 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $7.8699 whereas the lowest price it dropped to was $7.421. The 52-week range on NVCT shows that it touched its highest point at $11.80 and its lowest point at $4.44 during that stretch. It currently has a 1-year price target of $19.00. Beta for the stock currently stands at -0.25.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NVCT was down-trending over the past week, with a drop of -7.13%, but this was down by -21.84% over a month. Three-month performance dropped to -21.76% while six-month performance rose 64.85%. The stock gained 39.56% in the past year, while it has gained 6.34% so far this year. A look at the trailing 12-month EPS for NVCT yields -1.09 with Next year EPS estimates of -1.07. For the next quarter, that number is -0.25. This implies an EPS growth rate of 6.46% for this year and -3.21% for next year. EPS is expected to grow by 9.24% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -510.36%.
Float and Shares Shorts:
At present, 23.63 million NVCT shares are outstanding with a float of 10.55 million shares on hand for trading. On 2025-06-13, short shares totaled 2.12 million, which was 1016.0 higher than short shares on 1747267200. In addition to Mr. Ron Bentsur M.B.A. as the firm’s Co-Founder, Chairman, CEO & President, Dr. Enrique Poradosu Ph.D. serves as its Co-Founder, Executive VP, Chief Scientific & Business Officer.
Institutional Ownership:
Through their ownership of 0.09929 of NVCT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, NVCT reported revenue of $0.0 and operating income of -$5568000.0. The EBITDA in the recently reported quarter was -$5568000.0 and diluted EPS was -$0.27.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With NVCT analysts setting a high price target of 25.0 and a low target of 15.0, the average target price over the next 12 months is 19.0. Based on these targets, NVCT could surge 231.13% to reach the target high and rise by 98.68% to reach the target low. Reaching the average price target will result in a growth of 151.66% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.95683 being high and -$1.05651 being low. For NVCT, this leads to a yearly average estimate of -$1.00667.
